Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
OliX Pharmaceuticals, Inc., a clinical stage biotechnology company, focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases. The company's products pipeline includes OLX101 for skin scar; OLX102 for skin whitening; OLX103, an atopic dermatitis product; OLX104 for hair loss; OLX105, an anti-wrinkle product; and OLX106 for diabetic foot ulcer. Its products...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. Specifically, the stock is 'expensive' on P/E.
Target Price
The average target price of 226950.KQ is 160000 and suggests 11% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation
Buy
Sell